Therapy Pathways in the Treatment of Hormone Naive Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists. (ProComD)

Trial Profile

Therapy Pathways in the Treatment of Hormone Naive Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists. (ProComD)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Degarelix (Primary) ; Buserelin; Goserelin; Leuprorelin; Triptorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ProComD
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 21 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2016 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.
    • 21 Apr 2016 Planned primary completion date changed from 1 Mar 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top